COVID-19 Studies

 The William Harvey Clinical Research Centre, from where our patient-led organisation has grown, is a central part of the Barts Health research effort on COVID-19

RECOVERY

Updated 27/4/20

TrialsConnect has produced brief Study Summary sheets on a number of research studies. This is part of a programme to help clinical trials patients tell their ‘Trial Story’ to family and lay audiences.

Study Summaries for selected studies on COVID-19  can be downloaded here:

ACCORD
(BerGenBio)

REMAP-CAP

PRIEST

GenOMICC

ISARIC

Barts
BioResource

COVID-19 STUDY NEWS LINKS

His death will not be in vain…

Read the story of the first blood sample collected at Barts Health for the GenOMICC study.

Daily Telegraph, 21 May 2020


Followed up in The Guardian, 23/5/20 HERE

International Clinical Trials Day

Read about Barts Health success in recruiting patients to research studies HERE.


Download a copy of the Barts Health Research Engagement team guide to virtual celebration of International Clinical Trials Day HERE

Barts BioResource has been running for some time. It now stores records and samples from nearly 25,000 heart patients. It’s brief has now been extended so that records and samples from COVID-19 patients will be securely stored for use in research .

These new videos describe COVID-19 research to patients and relatives. They were produced by patient John Greenwood's company, Greenacre, for Barts Health NHS Trust and are available in several languages.The project was organised by Dr Manish Saxena of the William Harvey Clinical Research Centre working with Neeta Patel, Barts Health NHS Trust.

Training for the volunteer staff helping with this research is taking place at the William Harvey Clinical Research Centre, Charterhouse Square, where TrialsConnect is based.

Patients have been consulted on rapidly produced information and consent materials as well as having a representative on the coördinating group.

TRIALSCONNECT has worked alongside

This website makes use of cookies. Please see our privacy policy for details.

OK